01PePeptidesENHANCED

Retatrutide available at Ascension Peptides — Save 50% with code ENHANCED

Buy Retatrutide
TrendingCOA VerifiedInjectable

Retatrutide

Triple agonist (GLP-1 / GIP / Glucagon) researched for significant weight management effects

Half-life

~6 days

Typical Dose

2-12mg weekly (titrated up)

Format

Injectable

Purity

≥98%

Buy from Ascension — 50% off code ENHANCEDRead research

Overview

Retatrutide is a novel triple receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously [1,4]. Currently in late-stage clinical research, it has shown the most significant weight reduction effects of any peptide studied to date — surpassing both Semaglutide and Tirzepatide in head-to-head trials [1,2]. Phase 2 data also demonstrate benefits in metabolic dysfunction-associated steatotic liver disease [3].

Mechanism

Simultaneously activates three receptors: GLP-1 (satiety, insulin), GIP (insulin amplification), and Glucagon (energy expenditure) [4,5]. The combination produces both reduced caloric intake AND increased energy burn — a unique dual approach [1]. Preclinical work confirmed favorable receptor binding ratios that drive the metabolic profile [4].

Researched benefits

  • Highest weight reduction in clinical trials to date
  • Triple receptor activation (GLP-1, GIP, Glucagon)
  • Improved insulin sensitivity markers
  • Reduced appetite and slower gastric emptying
  • Once-weekly dosing protocol

Frequently asked

How does Retatrutide compare to Tirzepatide?

Retatrutide adds glucagon receptor agonism on top of Tirzepatide's GLP-1/GIP dual action. Clinical trials show ~24% weight reduction at 48 weeks vs Tirzepatide's ~21%. The added glucagon component appears to drive additional energy expenditure beyond appetite suppression alone.

Is Retatrutide approved?

Retatrutide is currently in Phase 3 clinical trials (TRIUMPH program) and is not yet FDA approved. It is available for research purposes only. Eli Lilly anticipates regulatory submissions in 2026 pending Phase 3 completion.

What's the half-life of Retatrutide?

Approximately 6 days, supporting once-weekly subcutaneous dosing. The long half-life is achieved through fatty acid acylation that promotes albumin binding, similar to Semaglutide's design strategy.

What's the typical research dose titration?

Phase 2 trials titrated from 2mg weekly upward over 4-week intervals to maximum doses of 4mg, 8mg, or 12mg weekly. Slow titration is essential to mitigate GI side effects, which are dose-dependent and most common during escalation.

How is Retatrutide reconstituted?

Bacteriostatic water is the standard diluent. For a 10mg vial, 2mL of bacteriostatic water yields 5mg/mL. Swirl gently — do not shake — and store refrigerated at 2-8°C after reconstitution.

Subcutaneous vs intramuscular for Retatrutide?

All clinical trials used subcutaneous administration (abdomen, thigh, or upper arm). Subcutaneous dosing produces the predictable absorption kinetics the molecule was designed for. IM administration has not been studied and is not recommended.

Scientific Literature

References

  1. [1]

    Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.

    New England Journal of Medicine · PubMed: 37366315

  2. [2]

    Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.

    The Lancet · PubMed: 37356446

  3. [3]

    Sanyal AJ, Kaplan LM, Frias JP, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease.

    Nature Medicine · PubMed: 38858523

  4. [4]

    Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.

    Cell Metabolism · PubMed: 36513063

  5. [5]

    Urva S, Coskun T, Loh MT, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.

    The Lancet · PubMed: 36240838

  6. [6]

    Knerr PJ, Mowery SA, Douros JD, et al. (2022). Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.

    Molecular Metabolism · PubMed: 35690347

  7. [7]

    Nauck MA, D'Alessio DA. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness.

    Cardiovascular Diabetology · PubMed: 36050763

  8. [8]

    Müller TD, Blüher M, Tschöp MH, DiMarchi RD. (2022). Anti-obesity drug discovery: advances and challenges.

    Nature Reviews Drug Discovery · PubMed: 34815532

  9. [9]

    Bossart M, Wagner M, Elvert R, et al. (2022). Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/glucagon receptor triagonist.

    Cell Metabolism · PubMed: 34986322

  10. [10]

    Frias JP, Bastyr EJ, Vignati L, et al. (2024). Triple hormone receptor agonism: pharmacology and clinical perspectives.

    Diabetes Care · PubMed: 38576421

  11. [11]

    Jastreboff AM, Kushner RF. (2023). New frontiers in obesity treatment: incretin-based therapeutics.

    Annual Review of Medicine · PubMed: 36400060

Citations are provided for educational purposes. Always verify primary sources before drawing research conclusions.

Ready to start your research

Get Retatrutide from Ascension Peptides

COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.

Buy Retatrutide now